Compare Stryker Corporation (SYK) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Victoria's Secret & Co — how do they compare? Stryker Corporation trades at $277.22 (market cap $106.24B), while Victoria's Secret & Co trades at $82.88 (market cap $6.91B). The key difference: Stryker Corporation is far larger — about 15.4× Victoria's Secret & Co's market cap, and Stryker Corporation pays a 1.27% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Victoria's Secret & Co for 34 Days on average.
| SYK | VSXY | |
|---|---|---|
Market Cap | $106.24B | $6.91B |
Volume | 2,982,001 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $388.35 | $99.97 |
52-Week Low | $269.75 | $28.25 |
Typical Hold Time | 21 Days | 34 Days |
Enterprise Value | $117.70B | $9.29B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Victoria's Secret (VSXY) trades at $81.83, down 4.62% today, but maintains strong technical momentum with a bullish moving average signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE. Recent news highlights the fashion show expansion and omnichannel growth strategy driving international sales momentum. Cash flow projections for 2026 show significant improvement to $334M net cash flow, indicating stronger financial health ahead.
The stock presents a compelling opportunity with 60% analyst buy ratings and an $86.80 consensus target offering 6% upside. However, elevated valuation multiples and recent margin pressure require careful monitoring. The company's Path to Potential initiative shows promising traction, but execution risks and competitive retail pressures remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
